CCEP
Coca-Cola Europacific Partners PLC
There isn't enough reported data to score CCEP yet.
CELH
Celsius Holdings, Inc.
CELH's fundamentals are strong and it looks cheap: trading at 35x earnings, less than half its usual 142x. Analysts expect strong earnings growth, though they disagree widely on how much.
CCEP Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Stable |
CCEP's profitability is currently strong, and its balance sheet is stable. There isn't enough data to rate its revenue and cash flow.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CCEP PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $78.02 | -33% |
| Fair | 21x | $102 | -13% |
| Current | 24x | $117 | — |
| Expensive | 27x | $128 | +9.8% |
Historical ranges are pointers, not guarantees.
CCEP's PE is 24x, but its earnings don't support one, so it isn't a reliable read right now.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH has the edge over CCEP in the historical PE scenario, which offers more potential upside but is not a forecast.
CCEP Forward outlook
There aren't enough analyst estimates for CCEP to show an outlook.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for CELH, with profitability improving. However, they disagree widely on these estimates.
CCEP Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $4.73 | +38% |
| Q2 2025 | $3.71 | -4.6% |
| Q4 2024 | $3.42 | -15% |
| Q2 2024 | $3.89 | -5.1% |
| Q4 2023 | $4.03 | +10% |
| Q2 2023 | $4.10 | +20% |
| Q4 2022 | $3.65 | +53% |
| Q2 2022 | $3.42 | +130% |
CCEP earned $4.73 per share over the past year, up 17% from the year before.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH has the edge over CCEP in the latest year-over-year earnings comparison.
CCEP Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.9B | +4.4% |
| Q4 2025 | $11.8B | +0.2% |
| Q2 2025 | $11.4B | +4.5% |
| Q4 2024 | $11.8B | +14% |
| Q2 2024 | $10.9B | +9.5% |
| Q4 2023 | $10.4B | +3.2% |
| Q2 2023 | $10B | +8.4% |
| Q4 2022 | $10B | +15% |
CCEP's revenue has grown year over year for 11 quarters in a row: $11.9B last quarter, up 9.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 14% | +2 points |
| Q4 2025 | 13% | +0.9 points |
| Q2 2025 | 13% | +0.3 points |
| Q4 2024 | 9.3% | -3.1 points |
| Q2 2024 | 12% | -0.1 points |
| Q4 2023 | 13% | -0.2 points |
| Q2 2023 | 13% | +4.2 points |
| Q4 2022 | 12% | +2.9 points |
CCEP's operating margin was 14% last quarter, up 2 points from the same quarter a year ago, near the top of its range since 2012.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH has the edge over CCEP in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over CCEP on profitability, with a higher operating margin.
CCEP Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $670.7M | -6.1% |
| Q4 2025 | $1.7B | +1.4% |
| Q2 2025 | $714.3M | -12% |
| Q4 2024 | $1.7B | +41% |
| Q2 2024 | $813.2M | -30% |
| Q4 2023 | $1.2B | +14% |
| Q2 2023 | $1.2B | -29% |
| Q4 2022 | $1.1B | -1.8% |
CCEP generated $4.8B in free cash flow over the past year, up 14% from the year before.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH still generates free cash flow, though less than at its 2025 peak: $269M over the past year.
CCEP Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2.2% | -10M shares |
| 1 year | -3% | -14M shares |
| 3 years | -2.4% | -11M shares |
| 5 years | +58% | +163M shares |
| Available history | -25% | -148M shares |
CCEP has the edge over CELH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $589.1M |
| Q4 2025 | — |
| Q2 2025 | $44.4M |
| Q4 2021 | — |
| Q2 2021 | — |
| Q4 2020 | — |
| Q2 2020 | $143.3M |
| Q4 2019 | $608.8M |
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has 255M diluted shares, down 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
CCEP Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 2.6x | Moderate |
| Q2 2025 | 3.1x | Elevated |
| Q4 2024 | 3.2x | Elevated |
| Q2 2024 | 3.3x | Elevated |
| Q4 2023 | 3.2x | Elevated |
| Q2 2023 | 3.4x | Elevated |
| Q4 2022 | 3.6x | Elevated |
| Q2 2022 | 3.9x | Elevated |
CCEP's net debt is about 2.6 years of its operating earnings (EBITDA), down from 3.2 years a year ago.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has more cash than debt.
CCEP Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.2 | Neutral |
| Stochastic | 88.6 | Overbought |
CCEP's weekly RSI is 67 (neutral) and its Stochastic is 89 (overbought).
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
CCEP PE vs Consumer Defensive Sector
| Metric | CCEP | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 19x | 22% above |
| PE % | 72 | 18 | 54 pts above |
CCEP has the edge over CELH on valuation relative to its sector.
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
CCEP Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $109.6 | 6.7% above |
| 20 week MA | $107.5 | 8.8% above |
| 50 week MA | $100.1 | 17% above |
| 100 week MA | $94.0 | 24% above |
| 200 week MA | $80.8 | 45% above |
CCEP has the edge over CELH on trend strength, trading above more of its moving averages.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 29% below its 200-week average.
CCEP Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $50.9 | $47.7 | -6.3% |
| 2021 | $47.7 | $55.2 | +16% |
| 2022 | $55.2 | $55.0 | -0.5% |
| 2023 | $55.0 | $66.7 | +21% |
| 2024 | $66.7 | $76.5 | +15% |
| 2025 | $76.5 | $91.7 | +20% |
| 2026 YTD | $91.7 | $116.9 | +28% |
CCEP has the edge over CELH on returns for 2026, with the stronger performance.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.